Amgen on Thursday reported a fourth-quarter profit trickle below Wall Street estimates, hurt by a steep decline in sales events of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses, and its interests fell more than 3 percent.
But the world’s biggest biotechnology attendance provided a 2018 earnings forecast range with a midpoint that question exceeded analysts’ estimates and announced a $10 billion share repurchase program and a humble effective tax rate due to U.S. tax reform.
Excluding items, Amgen earned $2.89 per dispensation, 14 cents below analysts’ average expectations, according to Thomson Reuters.
For 2018, Amgen prognostication adjusted earnings per share of $12.60 to $13.70 and revenue of $21.8 billion to $22.8 billion. Analysts were looking for earnings of $12.71 per share and $22.8 billion in takings.
“It’s a big slow-growing biopharmaceutical company,” said Cowen and Co analyst Eric Schmidt. “We’re all stay for them to do at least a modest size deal. They need another effect or two.”
Amgen projected a 2018 adjusted tax rate of 14 percent to 15 percent. Some other weighty drugmakers have announced rates of about 17 percent or 18 percent. AbbVie . amazed investors last week by announcing a 9 percent adjusted tax rate, hit the deck to 13 percent over five years.
Amgen said it arranges capital investments of about $3.5 billion over the next five years, with 75 percent of that in the Opinion States. The company said it decided to build a new biomanufacturing plant in the Synergetic States and will add jobs to build and run the facility. Amgen expects to tell the plant location in the second quarter.
Revenue for the quarter fell 3 percent to $5.8 billion, back in line with analysts’ expectations.
Enbrel sales fell 13 percent to $1.37 billion due to lop off demand and net selling price in a highly competitive market.
Sales of its next biggest issue, the infection fighter Neulasta, were flat at $1.11 billion.
Prolia for osteoporosis cultivated 24 percent to $463 million.
The company said it incurred $79 million in expenses in Puerto Rico for Cyclone Maria recovery and additional incremental expenses related to tax planning.
It proclaimed a fourth-quarter net loss of $4.26 billion, or $5.89 per share, as it took a $6.1 billion indict related to U.S. tax reform. That compared with a profit of $1.93 billion, or $2.59 per ration, a year ago.
Amgen shares fell to $179.35 in extended trading from a Nasdaq shut down at $185.56.